Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies


Sygnature Discovery’s scientific teams have extensive experience in this therapeutic area and have successfully delivered 5 clinical compounds and 4 preclinical compounds for our clients.

As a result of this experience, Sygnature’s teams are familiar with Medicinal Chemistry strategies to target drug delivery to the lung for a broad range of respiratory diseases, including infection (viral and fungal), inflammatory (severe Asthma and COPD) and lung remodelling (IPF).  For each therapeutic area and drug target, our medicinal chemistry design strategy, supported by the synthesis of bespoke compounds, seeks in the first instance, potency and duration of exposure in the lung. We use in vitro bioscience and DMPK assays to rank order compounds and enhance the chances of in vivo success. We appreciate what makes a good inhaled medicine.

Our highly experienced scientists utilise state-of-the-art technologies and are adept at developing bespoke assays, or adapting existing assays as necessary to meet project needs.  We have experience in developing in vitro assays utilising airway epithelial cells, endothelial cells, and alveolar macrophages.

Our mixed occupancy laboratories allow our integrated project teams involving Chemistry, DMPK, Computational Chemistry and Bioscience to work closely together with our clients to find the best solution to their current and future project requirements.  This close collaboration between the disciplines results in accelerated design-make-test-analyse (DMTA) cycles, to rapidly identify Structure-Activity Relationships (SAR), enable efficient compound optimisation and Candidate Drug delivery.  We offer a broad range of assay platforms and systems that provide a flexible approach to respiratory disease drug discovery and can be used to discover or profile new or existing targets, identify potential new medicines or novel mechanisms with the potential to impact the disease processes of interest.

Sygnature Discovery’s many assay platforms and systems include:

In addition, we have our own in-house human Blood Donor Panel, allowing easy access to immune and inflammatory cells from volunteer blood and can access additional ethically-sourced patient samples, including airway epithelial cells, endothelial cells and alveolar macrophages, through links with local hospitals, universities and commercial vendors.

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.

Oncology and Immuno-oncology

We have successfully delivered more than 16 pre-clinical oncology projects, utilising our Integrated Drug Discovery expertise to develop small molecule drug candidates to treat a variety of cancers such as leukaemia, breast and prostate cancer. From initial screening and profiling through to clinically relevant Biomarkers, our DMPK and bioscience group can provide full support for your discovery projects.



Diabetes is a metabolic disorder that is an increasingly prevalent disease worldwide. We have established assays to support the investigation of diabetic therapies including relevant functional assays. We also have access to tissue and blood from in vivo diabetic models through strategic collaborations.


Orphan Disease

Sygnature’s team of scientists have a strong track record of adding value to client projects in the field of rare and orphan diseases.  Sygnature’s advanced intellectual input and established relationships with providers of diseased tissue allows rapid progression of projects in this challenging therapeutic area.



Sygnature have a history of enabling discovery success in the field of anti-infectives. Our Medicinal Chemistry and Computational Chemistry teams have worked in close collaboration with many clients to design potent and efficacious compounds, resulting in the delivery of two preclinical candidates. Our Bioscience team can provide cytopathic effect and viability screening assays to assess compounds designed to inhibit virus attachment, entry or replication in human host cells.



Our scientists have a well-developed understanding of the challenges associated with the design and optimisation of compounds that target the central nervous system (CNS). Our experience is both broad, reaching across a number of neurodegenerative diseases (such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis) and neuropathic pain, and deep-rooted, with members of our senior team having 10+ years in CNS drug research.



We have an excellent track record of success in the field of respiratory diseases using our extensive in-house expertise, accelerating 5 compounds to the clinic and a further 4 into preclinical development for our clients. Our collaborative approach to drug discovery and our established network of KOLs in the field have been invaluable to the progression of our clients’ projects


Inflammation and Immunology

Our scientists have a rich heritage in this therapeutic area and provide significant experience in developing in vitro assays utilising Peripheral Blood Mononuclear Cells (PBMCs), T lymphocytes (e.g. CD4+/CD8+), leukocytes, and phagocytes, amongst others, that assess various inflammation and immunological biomarkers, processes, and endpoints.